Immunological tests and therapies in reproductive medicine

Minerva Ginecologica

Volumn 62, Issue 3, 2010, Pages 253-260

  Prakash, A ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Abortion, spontaneous; Allergy and immunology; Immunotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA DEFENSIN; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CHEMOKINE; ELAFIN; HEPARIN; HLA ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN; INTRALIPID; LACTOFERRIN; LIPID EMULSION; LOW MOLECULAR WEIGHT HEPARIN; LYSOZYME; POLYPEPTIDE ANTIBIOTIC AGENT; PREDNISONE; THYROID ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ALLOIMMUNITY; ANTIPHOSPHOLIPID SYNDROME; CELLULAR IMMUNITY; CONCEPTION; FERTILIZATION IN VITRO; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFERTILITY THERAPY; INNATE IMMUNITY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; REGULATORY T LYMPHOCYTE; REPRODUCTION; REVIEW; SPONTANEOUS ABORTION; STEROID THERAPY; TH1 CELL; TH2 CELL; THROMBOSIS; THROMBOSIS PREVENTION;

ABORTION, SPONTANEOUS; FEMALE; HUMANS; IMMUNOLOGIC TESTS; IMMUNOTHERAPY; PREGNANCY;

EID: 77957665264     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update 2009;15:517-35.
2. RCOG. The investigation and treatment of couples with recurrent miscarriage. Royal College of Obstetricians and Gynaecologists 2003.
3. King A, Boocock C, Sharkey AM, Gardner L, Beretta A, Siccardi AG et al. Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. J Immunol 1996;156:2068-76.
4. Fuzzi B, Rizzo R, Criscuoli L, Noci I, Melchiorri L, Scarselli B et al.HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol 2002;32:311-5. (Pubitemid 34173321)
5. Noci I, Fuzzi B, Rizzo R, Melchiorri L, Criscuoli L, Dabizzi S et al. Embryonic soluble HLA-G as a marker of developmental potential in embryos. Hum Reprod 2005;20:138-46.
6. Laird SM, Tuckerman EM, Cork BA, Linjawi S, Blakemore AI, Li TC. A review of immune cells and molecules in women with recurrent miscarriage. Hum Reprod Update 2003;9:163-74.
7. Emmer PM, Steegers EA, Kerstens HM, Bulten J, Nelen WL, Boer K et al. Altered phenotype of HLA-G expressing trophoblast and decidual natural killer cells in pathological pregnancies. Hum Reprod 2002;17:1072-80.
8. Le Bouteiller P, Blaschitz A. The functionality of HLA-G is emerging. Immunol Rev 1999;167:233-44.
9. Pandey MK, Thakur S, Agrawal S. Lymphocyte immunotherapy and its probable mechanism in the maintenance of pregnancy in women with recurrent spontaneous abortion. Arch Gynecol Obstet 2004;269:161-72. (Pubitemid 38374702)
10. Ober C, van der Ven K. Immunogenetics of reproduction: an overview. Curr Top Microbiol Immunol 1997;222:1-23.
11. Hedrick PW. HLA-sharing, recurrent spontaneous abortion, and the genetic hypothesis. Genetics 1988;119:199-204.
12. Medawar P. Some immunological and endocrinological problems raised by the evolution of viviparity in vertibrates. Symp Soc Exp Biol 1953:320-38.
13. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997;18:478-82.
14. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod 2004;10:347-53.
15. Zhao JX, Zeng YY, Liu Y. Fetal alloantigen is responsible for the expansion of the CD4(+)CD25(+) regulatory T cell pool during pregnancy. J Reprod Immunol 2007;75:71-81. (Pubitemid 47384866)
16. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002;2:656-63.
17. Ntrivalas EI, Kwak-Kim JY, Gilman-Sachs A, Chung-Bang H, Ng SC, Beaman KD, Mantouvalos HP et al. Status of peripheral blood natural killer cells in women with recurrent spontaneous abortions and infertility of unknown aetiology. Hum Reprod 2001;16:855-61.
18. Clifford K, Flanagan AM, Regan L. Endometrial CD56+ natural killer cells in women with recurrent miscarriage: a histomorphometric study. Hum Reprod 1999;14:2727-30.
19. Quenby S, Kalumbi C, Bates M, Farquharson R, Vince G. Prednisolone reduces preconceptual endometrial natural killer cells in women with recurrent miscarriage. Fertil Steril 2005;84:980-4. (Pubitemid 41417735)
20. Moffett A, Regan L, Braude P. Natural killer cells, miscarriage, and infertility. Bmj 2004;329:1283-5.
21. Nardo LG, Granne I, Stewart J. Medical adjuncts in IVF: evidence for clinical practice. Hum Fertil (Camb) 2009;12:1-13.
22. Rai R, Sacks G, Trew G. Natural killer cells and reproductive failure - theory, practice and prejudice. Hum Reprod 2005;20:1123-6.
23. Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update 2002;8:463-81. (Pubitemid 35175207)
24. Kaider AS, Kaider BD, Janowicz PB, Roussev RG. Immunodiagnostic evaluation in women with reproductive failure. Am J Reprod Immunol 1999;42:335-46.
25. Rushworth FH, Backos M, Rai R, Chilcott IT, Baxter N, Regan L. Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies. Hum Reprod 2000;15:1637-9.
26. Wilson R, Ling H, MacLean MA, Mooney J, Kinnane D, McKillop JH et al.Thyroid antibody titer and avidity in patients with recurrent miscarriage. Fertil Steril 1999;71:558-61.
27. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-15.
28. Bose P, Kadyrov M, Goldin R, Hahn S, Backos M, Regan L et al. Aberrations of early trophoblast differentiation predispose to pregnancy failure: lessons from the antiphospholipid syndrome. Placenta 2006;27:869-75.
29. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7. (Pubitemid 27047378)
30. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13. (Pubitemid 35246124)
31. King AE, Critchley HO, Kelly RW. Innate immune defences in the human endometrium. Reprod Biol Endocrinol 2003;1:116.
32. Borroni EM, Bonecchi R, Buracchi C, Savino B, Mantovani A, Locati M. Chemokine decoy receptors: new players in reproductive immunology. Immunol Invest 2008;37:483-97.
33. Mowbray JF, Gibbings C, Liddell H, Reginald PW, Underwood JL, Beard RW. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985;1:941-3.
34. Ober C, Karrison T, Odem RR, Barnes RB, Branch DW, Stephenson MD et al. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet 1999;354:365-9.
35. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002;107:387-93. (Pubitemid 36693642)
36. Clark DA, Chaouat G. Loss of surface CD200 on stored allogeneic leukocytes may impair anti-abortive effect in vivo. Am J Reprod Immunol 2005;53:13-20.
37. Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet 2006;23:1-13.
38. Coulam CB, Krysa L, Stern JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:333-7.
39. Kiprov DD, Nachtigall RD, Weaver RC, Jacobson A, Main EK, Garovoy MR. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. Am J Reprod Immunol 1996;36:228-34.
40. Stricker RB, Steinleitner A, Bookoff CN, Weckstein LN, Winger EE. Successful treatment of immunologic abortion with low-dose intravenous immunoglobulin. Fertil Steril 2000;73:536-40. (Pubitemid 30109651)
41. Stephenson MD, Dreher K, Houlihan E, Wu V. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998;39:82-8.
42. Intravenous immunoglobulin in the prevention of recurrent miscarriage. The German RSA/IVIG Group. Br J Obstet Gynaecol 1994;101:1072-7.
43. Christiansen OB, Mathiesen O, Husth M, Rasmussen KL, Ingerslev HJ, Lauritsen JG et al. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Hum Reprod 1995;10:2690-5.
44. Christiansen OB, Pedersen B, Rosgaard A, Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod 2002;17:809-16.
45. Perino A, Vassiliadis A, Vucetich A, Colacurci N, Menato G, Cignitti M et al. Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 1997;12:2388-92.
46. Jablonowska B, Selbing A, Palfi M, Ernerudh J, Kjellberg S, Lindton B. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Hum Reprod 1999;14:838-41.
47. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. Jama 1995;273:1865-70.
48. ASRM. Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss. Fertil Steril 2006;86:S226-7.
49. Clark DA. Should anti-TNF-alpha therapy be offered to patients with infertility and recurrent spontaneous abortion? Am J Reprod Immunol 2009;61:107-12.
50. Clark DA, Chaouat G, Arck PC, Mittruecker HW, Levy GA. Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase). J Immunol 1998;160:545-9.
51. Clark DA, Arck PC, Chaouat G. Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level. Am J Reprod Immunol 1999;41:5-22. (Pubitemid 29108227)
52. Clark DA, Yu G, Arck PC, Levy GA, Gorczynski RM. MD-1 is a critical part of the mechanism causing Th1-cytokine-triggered murine fetal loss syndrome. Am J Reprod Immunol 2003;49:297-307.
53. Winger EE, Reed JL, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 2009;61:113-20.
54. Toder V, Fein A, Carp H, Torchinsky A. TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J Assist Reprod Genet 2003;20:73-81.
55. Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2004;3:391-403. (Pubitemid 39242714)
56. Battistella FD, Widergren JT, Anderson JT, Siepler JK, Weber JC, MacColl K. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. J Trauma 1997;43:52-8; discussion 58-60.
57. Granato D, Blum S, Rossle C, Le Boucher J, Malnoe A, Dutot G. Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. JPEN J Parenter Enteral Nutr 2000;24:113-8.
58. Mayer K, Meyer S, Reinholz-Muhly M, Maus U, Merfels M, Lohmeyer J et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 2003;171:4837-43. (Pubitemid 37310605)
59. Roussev RG, Ng SC, Coulam CB. Natural killer cell functional activity suppression by intravenous immunoglobulin, Intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol 2007;57:262-9.
60. Loo LS, Tang JP, Kohl S. Inhibition of cellular cytotoxicity of leukocytes for herpes simplex virus-infected cells in vitro and in vivo by Intralipid. J Infect Dis 1982;146:64-70. (Pubitemid 12045337)
61. Roussev RG, Acacio B, Ng SC, Coulam CB. Duration of intralipid's suppressive effect on NK cell's functional activity. Am J Reprod Immunol 2008;60:258-63.
62. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001;166:5018-26.
63. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J et al. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 2003;126:176-85. (Pubitemid 36068568)
64. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, Ellis SA et al. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med 1999;189:1149-56.
65. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999;189:1093-100.
66. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006:CD000112.
67. Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2000:CD000112.
68. Bider D, Hourvitz A, Tur Kaspa I, Dirnfeld M, Dor J. Dexamethasone supplementation to gonadotropin stimulation for in vitro fertilization in polycystic ovarian disease. J Assist Reprod Genet 1999;16:233-5. (Pubitemid 29226905)
69. Rein MS, Jackson KV, Sable DB, Thomas PP, Hornstein MD. Dexamethasone during ovulation induction for in-vitro fertilization: a pilot study. Hum Reprod 1996;11:253-5.
70. Lee KA, Koo JJ, Yoon TK, Do BR, Ko JJ, Cha KY. Immunosuppression by corticosteroid has no effect on the pregnancy rate in routine in-vitro fertilization/embryo transfer patients. Hum Reprod 1994;9:1832-5.
71. Mottla GL, Smotrich DB, Gindoff PR, Stillman RJ. Increasing clinical pregnancy rates after IVF/ET. Can immunosuppression help? J Reprod Med 1996;41:889-91.
72. Bider D, Amoday I, Tur-Kaspa I, Livshits A, Dor J. The addition of a glucocorticoid to the protocol of programmed oocyte retrieval for in-vitro fertilization - a randomized study. Hum Reprod 1996;11:1606-8.
73. Ubaldi F, Rienzi L, Ferrero S, Anniballo R, Iacobelli M, Cobellis L, Greco E. Low dose prednisolone administration in routine ICSI patients does not improve pregnancy and implantation rates. Hum Reprod 2002;17:1544-7.
74. Cohen J, Malter H, Eisner C, Kort H, Massey J, Mayer MP. Immunosuppression supports implantation of zona pellucida dissected human embryos. Fertil Steril 1990;53:662-5. (Pubitemid 20143048)
75. Taniguchi F. Results of prednisolone given to improve the outcome of in vitro fertilization-embryo transfer in women with antinuclear antibodies. J Reprod Med 2005;50:383-8. (Pubitemid 40863953)